Intrapleural BCG in Operable Lung Cancer

Lowe, J B; Shore, D. F.; Iles, P.B.; Langman, M. J. S.; Baldwin, Robert

doi:10.1016/s0140-6736(80)90551-6

Cited by 49 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A controlled randomized trial of intrapleural BCGr in surgically resected lung cancer carried out in this country, failed to confirm the experience of McNeally (Lowe et al, 1980). The authors point out various minor differences in the treatment given, but it seems unlikely that these were sufficient to explain the differences in the results between the two trials.…”

Section: Resultsmentioning

confidence: 93%

Failure of specific active immunotherapy in lung cancer

Souter¹,

Gill²,

Gunning³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

A randomized trial comparing routine follow-up with a treatment regimen aimed at increasing specific anti-tumour immunity has been carried out in 95 patients after total surgical excision of lung cancer (not small-cell). Treatment consisted of inoculation with an autologous irradiated suspension of tumour cells combined with a small dose of C. parvum given intradermally during convalescence. Although treatment was associated with virtually no side effects, there has been no apparent benefit and input to the trial has now stopped.

show abstract

Section: Resultsmentioning

confidence: 93%

Failure of specific active immunotherapy in lung cancer

Souter¹,

Gill²,

Gunning³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…However, the low survival rate of their control group undermines the validity of their conclusions. Other studies have failed to confirm an improvement in survival asso-elated with the use of intrapleural BCG [1,13,21,33], possibly because of the use of a different strain of BCG. More recent studies, using the same Tice BCG as McKneally et al were unable to detect any beneficial effect of intrapleural BCG [20,28,42].…”

Section: Discussionmentioning

confidence: 99%

Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report

Bakker

Nijhuis-Heddes

Velde

1986

Cancer Immunol Immunother

View full text Add to dashboard Cite

Of a total study group of 99 patients 56 received intrapleural BCG in three different dosages (5 patients 16 X 10(6), 25 patients 32 X 10(6), and 26 patients 64 X 10(6) culturable particles) following resection treatment for lung cancer. This study group was compared with an historical control population, very closely matched with regard to age, sex, stage of disease, histology and type of operation. Although the clinical condition of the patients selected for BCG treatment was above average, no survival benefit ensued from the intrapleural BCG. On the contrary, disease-free survival in BCG receivers with stage I and II squamous cell carcinoma was shortened significantly at 2 years follow-up due to the earlier appearance of local recurrences, with the same tendency still present after 5 years. This observation suggests an enhancement of tumour growth by the intrapleural BCG treatment. This alarming phenomenon could be a warning to clinicians when planning clinical immunotherapy trials to be aware of the potentially deleterious effects of such treatment.

show abstract

“…Subsequent studies showed a survival benefit for stage I lung cancer patients receiving intrapleural BCG but no benefit for patients with resectable stage II and III disease [20]. There has been at least one negative intrapleural BCG trial [17], and one positive trial reported by Wright et al [37]. A large cooperative trial by the Lung Cancer Study Group has not yet been reported.…”

Section: Discussionmentioning

confidence: 99%